Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$173.91MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Bobak R. Azamian
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 370
- Beta
- 0.54
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 7.61
Financials
Revenue
$173.91M+420.2%Net Income
$-18.55MEBITDA
$-12.68MFree Cash Flow
$62.70MEPS (diluted)
$-0.43Shares Outstanding (diluted)
43.39M+912.6%Operating Expenses
$181.71MCash & Debt
$449.69MReturn of Capital
$0.00Revenue by Segment (annual)
$451.36MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $451.36M | $-66.42M | $-1.59 |
| 2024 | $182.95M | $-115.55M | $-3.07 |
| 2023 | $17.45M | $-135.89M | $-4.62 |
| 2022 | $25.82M | $-62.09M | $-2.52 |
| 2021 | $57.03M | $-13.83M | $-0.67 |
| 2020 | $0.00 | $-26.81M | $-1.32 |
| 2019 | $0.00 | $-4.67M | $-0.24 |
| 2018 | $0.00 | $-1.32M | $-0.31 |
Valuation
TARShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+66.67%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·17d ago·Neutral
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it expects to present 11 scientific abstracts at the American Academy of Optometry (AAOpt) 2026 Annual Meeting, taking place Sept. 30–Oct. 3 in Anaheim, California.
View source ↗ - Newsglobenewswire.com·42d ago·Neutral
…erapy Strengthens Tarsus' differentiated pipeline and leadership in eye care IRVINE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it has completed its previously announced acquisition of Alkeus Pharmaceuticals, Inc., a privately held retinal disease-focused biotechnology company.
View source ↗ - Newsglobenewswire.com·43d ago·Negative
Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Disease Daily treatment with oral gildeuretinol met the primary endpoint and resulted in a statistically significant reduction in the growth rate of retinal atrophic lesions compared to untreated group. Gildeuretinol was well tolerated with no patient-reported events of dark adaptation delays or night blindness.
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
Tarsus to Participate in Upcoming Investor Conferences IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th H.C.
View source ↗ - Newsglobenewswire.com·53d ago·Negative
Alkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt Disease CAMBRIDGE, Mass., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted Orphan Drug Designation for oral gildeuretinol for the trea
View source ↗
Earnings
Tue, Nov 3(in 2 weeks)
Consensus estimate $-1.47 per share
Typical surprise +7.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.43 vs $-0.19miss
- Wed, May 6$-0.16 vs $-0.40beat
- Mon, Feb 23$-0.20 vs $-0.10miss
- Tue, Nov 4$-0.30 vs $-0.35beat
- Wed, Aug 6$-0.48 vs $-0.33miss
- Thu, May 1$-0.64 vs $-0.69beat
Estimates and results for TARS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TARS officers and directors.
- Bought
- —
- Sold
- $14.9m
0 trades
45 trades
- Link William J Phdsold
- Link William J Phdsold
- Link William J Phdsold
- Azamian Bobak R.sold
- Azamian Bobak R.sold
- Lin Elizabeth Yeusold
- Lin Elizabeth Yeusold
- Lin Elizabeth Yeusold
55 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TARS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.